drugset / Trial / NCT04302025
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
Timeline
- Start
- 2020-11-06
- Primary completion
- 2026-11-30
- Completion
- 2030-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alectinib | Small molecule | — | Oral |
| Subject | Atezolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Cobimetinib | Small molecule | — | Oral |
| Subject | Divarasib | Small molecule | — | Oral |
| Subject | Entrectinib | Small molecule | — | Oral |
| Subject | Pralsetinib | Small molecule | — | Oral |
| Subject | Vemurafenib | Small molecule | — | Oral |